Clinical experience with orphan drugs for rare metabolic diseases

Area of Science:

• Pharmacology and Therapeutics
• Pediatric Medicine
• Rare Diseases

Background:

• Inborn errors of metabolism (IEMs) represent a diverse group of rare orphan diseases.
• Current treatments primarily include diet, enzyme, and coenzyme replacement therapies.
• Limited patient populations and studies characterize IEMs, necessitating research on therapeutic options.

Purpose of the Study:

• To evaluate the effectiveness of orphan drugs in pediatric patients diagnosed with inborn errors of metabolism.
• To analyze the outcomes and tolerability of specific orphan drug treatments in a real-world clinical setting.

Main Methods:

• A 24-month retrospective descriptive study was conducted.
• Data were collected from pediatric patients with diagnosed IEMs treated at a general hospital.
• Included patients attending the pharmacy clinic or Day-Care Unit.

Main Results:

• Fifteen pediatric patients with a median age of 17.8 years were included, treated with nine distinct orphan drugs.
• Seven types of IEMs were represented, including phenylketonuria, urea cycle defects, Gaucher, Niemann-Pick, Hunter's disease, acid lipase deficiency, and mitochondrial diseases.
• Orphan drugs constituted 1.3% of hospital drug expenditures, with varying degrees of clinical effectiveness from asymptomatic outcomes to modest symptomatic improvement; patient tolerance was generally good.

Conclusions:

• Orphan drugs for IEMs exhibit a manageable toxicity profile but demonstrate considerable variability in effectiveness.
• These specialized medications represent a significant economic burden on healthcare systems.
• The cost-effectiveness of orphan drugs remains debatable due to high acquisition costs and inconclusive clinical evidence.